Prosthetic (Prosthesis) devices, such as an artificial leg, that replace a part of the body. Prostheses are typically used to replace parts lost by injury (traumatic) or missing from birth (congenital) or to supplement defective body parts. Inside the body, artificial heart valves are in common use with artificial hearts and lungs seeing less common use but under active technology development. Other medical devices and aids that can be considered prosthetics include artificial eyes, palatal obturator, gastric bands, and dentures.
Lightning fast connections between robotic limbs and the human brain may be within reach for injured soldiers and other amputees with the establishment of a multimillion-dollar research center led by SMU engineers.
Genetically closely related skin bacteria that have developed resistance to several different antibiotics and that can cause intractable care-related infections are found and seem to be spreading within and between hospitals in Sweden.
Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,776,085 B2, covering an improved knee implant prosthesis that features a monoblock ceramic tibial component for articulation with natural or prosthetic (resurfaced) femoral surfaces.
Christian Kandlbauer, who lost both of his arms in a high voltage accident, uses a unique development which until recently sounded almost like science fiction: An arm prosthesis, the first of its kind in the world, which he controls solely through the power of his mind.
When Doris Snyder celebrated her 102nd birthday on August 10, she was that much closer to the expected birth of her first great-granddaughter who's due to arrive early September. She is very excited about the milestone, which might not have been possible were it not for a cutting-edge, experimental procedure that replaced one of Doris' heart valves weeks earlier when she was 101. The valve had been rendered useless by aortic valve stenosis—hardening from calcium deposits that restrict the flow of blood from the heart.
Atrium Medical Corporation was recently named as a defendant, along with Endologix, Inc., of Irvine, CA, in a lawsuit brought by C.R. Bard in U.S. District Court in Arizona. The suit involves a patent, U.S. No. 6,436,135, issued to Bard in 2002 related to prosthetic vascular grafts made of ePTFE (expanded polytetrafluoroethylene). Atrium has been involved in discussions with Bard management regarding this patent for several years.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular Graft" patent (U.S. Patent No. 6,436,135).
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
Our belief as to whether we will likely succeed or fail at a given task-and the consequences of winning or losing-directly affects the levels of neural effort put forth in movement-planning circuits in the human cortex, according to a new brain-imaging study by neuroscientists at the California Institute of Technology.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.
According to new dental reports by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for dental implants is expected to regain double-digit growth by 2013, and will help drive the dental prosthetic market to reach over 82 million prosthetic placements by 2016.
The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States. The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Professor John Fisher from The University of Leeds is speaking today (14 July) at the UK National Stem Cell Network Annual Science Meeting in Nottingham about his team's research into how biological scaffolding will pave the way for off- the-shelf tissue transplants.
As the nation prepares to celebrate Independence Day with parades and barbecues, America's veterans face a new tax on prosthetic limbs and other vital medical devices.
PolyTouch Medical Ltd., a leading developer of laparoscopic soft tissue prosthetic placement technologies, today announced that it has received broad FDA 510(k) clearance to commercialize PatchAssist. PatchAssist is an innovative laparoscopic surgical instrument that enables accurate and rapid delivery and placement of soft tissue prosthetics for a variety of procedures, including laparoscopic ventral hernia repair.
SensAble Technologies, Inc, the leading provider of dental restoration design and fabrication solutions, haptic devices and 3D modeling software, announced that Dental Prosthetic Services has joined the SensAble Authorized Production Center (SAPC) Program.
Queen's University Brian Amsden is hoping that in about 10 years a tendon, spinal cord or heart valve will be able to regenerate itself after an injury or disease. The chemical engineering professor, along with scientists from the University of Western Ontario and University of Toronto, is currently trying to develop microscopic polymer fibers to help rebuild human tissue and speed the healing process.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.